JNJ240830P146000
- 0.27
- 0.000.00%
Johnson & Johnson Newsroom
Johnson & Johnson Options Spot-On: On August 26th, 118K Contracts Were Traded, With 364.22K Open Interest
Express News | J&J - Peter M. Fasolo, Executive Vice President, Chief Human Resources Officer (Chro), Has Elected to Retire
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa
Express News | J&J - Mulholland Will Also Be Appointed as a Member of Johnson & Johnson's Executive Committee, Effective October 1, 2024
Express News | Johnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
Market Chatter: Johnson & Johnson Negotiates With Opposing Lawyers on $6.48 Billion Talc Settlement
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Johnson & Johnson To Go Ex-Dividend On August 27th, 2024 With 1.24 USD Dividend Per Share
Johnson & Johnson (NYSE:JNJ) Has A Pretty Healthy Balance Sheet
Is Johnson & Johnson (JNJ) The Best Among The S&P 500 Dividend Aristocrats According to Hedge Funds?
Investors in Johnson & Johnson (NYSE:JNJ) Have Seen Notable Returns of 46% Over the Past Five Years
Johnson & Johnson Continues Gains for Eight Straight Sessions
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
J&J Reportedly Seeking Additional Support for Talc Bankruptcy Plan
Johnson & Johnson Unveils New Strategy on Hospital Drug-Discount Program: Wall Street Journal
Johnson & Johnson Unit Gets European Approval for Cancer Treatment
Express News | Johnson & Johnson - European Commission Approves Balversa®▼ (Erdafitinib) for Adult Patients With Unresectable or Metastatic Urothelial Carcinoma
Express News | U.S. CDC Says For This Season Peak Hospitalizations For For Flu And Covid Combined Is Forecasted To Be Similar Or Slightly Improved Over Last Season; Covid Continues To Cause More Serious Disease Than Flu